Research Presented by Ģý North America at Kidney Week 2021 Demonstrates Commitment to Improving Dialysis Care
40 Affiliated Abstracts Available at American Society of NephrologyĢýs Virtual Conference
WALTHAM, Mass. Ģý Nov. 4, 2021 Ģý(FMCNA), the nationĢýs leading provider of kidney care products and services, today announced the presentation of 40 company-affiliated abstracts at the American Society of NephrologyĢýs (ASN), which runs virtually from Nov. 4-7. These publications include insights related to the use of artificial intelligence to advance care, maintaining patients on home therapies, COVID-19Ģýs impact on patients with kidney failure and vaccine response, as well as other clinical research experiences and advancements.
The research includes a virtual oral presentation of the abstract ĢýĢý which evaluated deidentified data from more than 16,000 new peritoneal dialysis (PD) patients at Fresenius Kidney Care centers in order to determine specific associations between fluid-related clinical factors and technique failure.
ĢýThe depth of scientific works presented demonstrates our ongoing commitment across the company to generate new insights that can improve care delivery and patient outcomes,Ģý said Dr. Robert Kossmann, Chief Medical Officer for FMCNA. ĢýOur focus on research and data analytics has helped us address the ongoing COVID-19 pandemic, while also examining innovations that can have a positive impact for people living with kidney failure.Ģý
The annual symposium, held virtually again in 2021, is one of the most significant gatherings of kidney professionals in the world. Some of the other abstracts being presented by Ģý, and now available online as part of ASNĢýs Kidney Week 2021, include:
- . Two machine learning models were built and showed good discrimination between patient risk categories for both short- and long-term timeframes. These tools may offer the potential to improve care for ĢýfailingĢý PD patients and reduce modality transitions.
- . Timely detection of peritonitis in patients undergoing peritoneal dialysis is critical to lower the risk of catheter loss, morbidity, and mortality. A smartphone app was developed that can distinguish peritonitis from normal peritoneal dialysis effluent samples.
- INitiativeS on advancing PatientsĢý outcomes In REnal disease (INSPIRE) is an academia and industry collaboration set forth to identify critical investigations/models needed to advance the practice of nephrology. A machine learning model was constructed, and it appears to have suitable performance for identifying a patientĢýs 30-day risk for GI bleed hospitalization.
- . As data on the persistence of COVID-19 antibodies against SARS-CoV-2 in hemodialysis patients from the U.S. is still scarce and an association with race and ethnicity is unknown, this abstract explores antibody dynamics in maintenance hemodialysis patients from three U.S. states with a diverse racial and ethnic background.
- . This abstract presents data suggesting available viral vector based vaccine against the SARS-CoV-2 virus may not be as effective in producing AB response in dialysis patients when compared to available mRNA vaccines.
- Despite different patient characteristics and treatment patterns in the 2014 and 2018 cohorts, HD patients from both cohorts had improvements in sP with fewer pills/day after SO conversion.
Ģý Ģý North America
Ģý North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities and outpatient cardiac and vascular labs, Ģý North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the worldĢýs largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. For more information, visit the FMCNA website at.
